Biomarker discovery in neurodegenerative diseases: a proteomic approach.
about
Neuronal dark matter: the emerging role of microRNAs in neurodegenerationBiomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomicsGenomic and proteomic responses to environmentally relevant exposures to dieldrin: indicators of neurodegeneration?"Gestaltomics": Systems Biology Schemes for the Study of Neuropsychiatric Diseases.Blood-based biomarkers for Parkinson's diseaseBiomarkers for cognitive impairment in Parkinson disease.Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease.Biological markers and Alzheimer disease: a canadian perspectiveAn investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach.Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.Bridging molecular genetics and biomarkers in lewy body and related disordersPolyphenols as therapeutic molecules in Alzheimer's disease through modulating amyloid pathways.Proteomics of gliomas: initial biomarker discovery and evolution of technology.Premotor biomarkers for Parkinson's disease - a promising direction of research.Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approachesProteomic profiling in MPTP monkey model for early Parkinson disease biomarker discoveryPlasma proteomics for the identification of Alzheimer disease.Redox Proteomic Profiling of Specifically Carbonylated Proteins in the Serum of Triple Transgenic Alzheimer's Disease Mice.Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells.Proteomics in Parkinson's disease: current trends, translational snags and future possibilities.Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson's disease.Understanding the molecular basis of Parkinson's disease, identification of biomarkers and routes to therapy.Brain banks as key part of biochemical and molecular studies on cerebral cortex involvement in Parkinson's disease.Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.Role of proteomics in biomarker discovery and psychiatric disorders: current status, potentials, limitations and future challenges.Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery.Biosensor technology: recent advances in threat agent detection and medicine.Proteomics as an innovative tool to investigate frontotemporal disorders.Quantitative proteomic analysis reveals mitochondrial protein changes in MPP(+)-induced neuronal cells.Cerebrospinal Fluid Total Tau is Increased in Normal Pressure Hydrocephalus Patients who Undergo Successful Lumbar Drain Trials.Non-Adhesive Behavior of New Nanostructured PNIPAM Surfaces Towards Specific Neurodegenerative Proteins: Application to Storage and Titration of Tau ProteinsAlzheimer disease pathology and the cerebrospinal fluid proteome
P2860
Q26859224-66BBAD77-5710-44ED-A3D7-2EEE48BFA64AQ27024518-DF84DBD8-F207-4D0B-A9A3-68CEA1F28443Q28382869-75AB7CE7-1697-443A-B125-093DC961F532Q33651168-449AA06C-9CFA-4BBD-BD1A-78CEE044ECFDQ33804255-2444BFC3-E762-49C7-B14E-C14A15C6949BQ33896664-5ACD5CD2-1E2E-465F-A42B-9D0AC4CBF50BQ34032608-9E7B5FB3-F7C6-4B79-A7B6-79389112DDACQ34089784-59B75655-7149-48B2-95F1-8E89E82211A1Q34616336-1B2F2042-DF24-47FF-B535-46F0C0BE44AFQ35034130-CD94D0E7-1EB8-4865-881B-4F847B51FD90Q35094391-3676838E-B6ED-41C3-BC95-6FD6806BE4C3Q35168349-DF98720D-5E14-4A46-BC9F-D147F7D25106Q35170365-6CA4F7C3-DD71-4F6A-BAF8-3279834E3942Q36444517-5D58C2AF-7386-49F7-8A88-A0AB5263C30CQ36530897-4821B1A7-CB36-4891-A81A-D5946B089E07Q36598403-D7274A77-A88F-4099-9D2D-504A1A757741Q36767124-002E02BD-5F39-4BA9-8934-D30E7EA519ADQ36846943-4CF64C2F-7D67-4A31-B9E8-AB4C14868596Q37381903-18A46B7E-E553-446C-859B-5B3CCA40FFEDQ37685124-7022A88C-EC25-4299-8C6C-CB73748EDD0FQ37688034-F5E1BED6-BE8E-45C1-A405-6E6F54073F19Q37775037-54ED63E6-DDA6-4BB5-B414-01EAB536BB03Q37982151-0F3A0FAC-5748-43A9-8661-5CC7C2B3EF6EQ38021940-1C81D51F-4D37-4BF6-B950-73194F37A637Q38027217-1CD94A60-78DA-47C7-AABD-B716838772A7Q38058054-ACCCAEB4-2AC2-4713-AB1C-03C4C4EB2AC8Q38121489-22071186-0FBE-4D93-A6C4-77BF496E38F9Q38802995-BE6C6386-8925-47ED-BB11-26009E2D5E6CQ38997384-1C823B45-D2D2-4F91-9FF0-B40467F05C6FQ41065539-E106FB4E-C1DE-4348-8B82-1188CEDAAA54Q57342789-342491DC-A9A5-4C63-8A12-491BDA308722Q58857913-EE432DEF-DEC9-4EF2-A567-C4D087C03D30
P2860
Biomarker discovery in neurodegenerative diseases: a proteomic approach.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Biomarker discovery in neurodegenerative diseases: a proteomic approach.
@ast
Biomarker discovery in neurodegenerative diseases: a proteomic approach.
@en
Biomarker discovery in neurodegenerative diseases: a proteomic approach.
@nl
type
label
Biomarker discovery in neurodegenerative diseases: a proteomic approach.
@ast
Biomarker discovery in neurodegenerative diseases: a proteomic approach.
@en
Biomarker discovery in neurodegenerative diseases: a proteomic approach.
@nl
prefLabel
Biomarker discovery in neurodegenerative diseases: a proteomic approach.
@ast
Biomarker discovery in neurodegenerative diseases: a proteomic approach.
@en
Biomarker discovery in neurodegenerative diseases: a proteomic approach.
@nl
P2860
P1476
Biomarker discovery in neurodegenerative diseases: a proteomic approach
@en
P2093
Jing Zhang
W Michael Caudle
P2860
P304
P356
10.1016/J.NBD.2008.09.004
P50
P577
2008-09-26T00:00:00Z